Market Cap: $101.2M
II
Immunic, Inc.
IMUX
NASDAQ (NASDAQ Global Select)USD
Market Cap: $101.2M
Immunic Inc (Ticker: IMUX), a biotechnology company at the forefront of developing oral therapies for neurologic diseases, is actively engaging with the medical and investment community through its up…
Immunic Inc. (Ticker: IMUX) has secured Erik Lundgren as its new Chief Executive Officer, effective May 22, 2026, marking a significant transition for the biotechnology company focused on innovative o…
Immunic, Inc. (Ticker: IMUX) has recently appointed Michael "Mike" W. Bonney as Chair of its Board of Directors, a move anticipated to have significant implications for the company's future, particula…
Immunic, Inc. (NASDAQ:IMUX) is advancing its mission to deliver innovative therapies for autoimmune diseases and cancers, with a major focus on its leading candidate, vidofludimus calcium (IMU-838). C…
Immunic Strengthens Leadership Amidst Regulatory Milestones Immunic, Inc., a late-stage biotechnology company specializing in innovative oral therapeutics for neurologic diseases, announces the appoin…
Immunic Secures Key European Patent for Vidofludimus Calcium, Strengthening Its Intellectual Property Portfolio Immunic, Inc. announces the granting of a crucial European patent, EP3713554, for its le…
Immunic Secures Key European Patent for Vidofludimus Calcium Immunic, Inc., a late-stage biotechnology company specializing in novel oral therapies for neurological and gastrointestinal disorders, ach…
Immunic, Inc. Expands Engagement at Key Healthcare Conferences Immunic, Inc., a late-stage biotechnology company, is actively reinforcing its presence within the biotech community through its particip…
Immunic Inc: Shifting Sentiment in Short Interest Reflects Market Dynamics Immunic Inc. (NYSE: IMUX) experiences a notable shift in market sentiment, evidenced by a 7.19% decline in its short interest…
Immunic raises cash to advance multiple sclerosis candidate toward market Funding underwrites transition from R&D to commercial-stage for vidofludimus calcium Immunic, the German-origin biopharma deve…
Immunic's Strategic Positioning in Neurologic and Gastrointestinal Therapies Immunic, Inc., a late-stage biotechnology company, solidifies its commitment to developing innovative oral therapies for ne…
### Immunic Advances in Autoimmune Disease Treatment Immunic, a clinical-stage biopharmaceutical company, makes significant strides in developing therapies for autoimmune diseases. The company focuses…
Immunic Strengthens Presence in Biotechnology Conferences to Showcase Innovative Therapies Immunic, Inc., a biotechnology firm specializing in small molecule therapies for chronic inflammatory and aut…
Immunic Advances Research on Chronic Inflammatory Diseases at Key Conferences Immunic, Inc., a biotechnology company focused on innovative treatments for chronic inflammatory and autoimmune diseases,…
Immunic Showcases Promising Data for Vidofludimus Calcium at ECTRIMS 2025 Immunic, Inc., a biotechnology company specializing in oral small molecule therapies for chronic inflammatory and autoimmune d…
Immunic Showcases Promising Data on Vidofludimus Calcium at ECTRIMS 2025 Immunic, Inc., a biotechnology firm dedicated to developing oral therapies for chronic inflammatory and autoimmune diseases, dr…
Immunic Strengthens Patent Portfolio for Vidofludimus Calcium in Multiple Sclerosis Treatment Immunic, Inc., a biotechnology company specializing in orally administered therapies for chronic inflammat…
Immunic Showcases Advancements in Multiple Sclerosis Research at Key Conferences Immunic, Inc., a biotechnology firm specializing in orally administered small molecule therapies for chronic inflammato…
Immunic Highlights Key Presentations at Upcoming Scientific Conferences Immunic, Inc., a biotechnology firm dedicated to developing oral therapies for chronic inflammatory and autoimmune diseases, is…
Immunic Inc Seeks Advancement in Multiple Sclerosis Treatment Amid Industry Challenges Immunic Inc is making significant progress in the biotechnology sector, particularly focused on relapsing multipl…
Immunic Inc. Advances in Multiple Sclerosis Treatment amid Leadership Changes Immunic Inc. is making significant progress in the biotechnology sector, particularly focused on developing treatments for…